GC Biopharma Corp. (KRX:006280)
South Korea · Delayed Price · Currency is KRW 134,300
+4,600 (3.55%)
At close: Nov 26, 2025
GC Biopharma Revenue
GC Biopharma had revenue of 609.49B KRW in the quarter ending September 30, 2025, with 31.11% growth. This brings the company's revenue in the last twelve months to 1.93T, up 17.66% year-over-year. In the year 2024, GC Biopharma had annual revenue of 1.68T with 3.27% growth.
Revenue (ttm)
1.93T
Revenue Growth
+17.66%
P/S Ratio
0.79
Revenue / Employee
947.30M
Employees
2,042
Market Cap
1.53T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.68T | 53.25B | 3.27% |
| Dec 31, 2023 | 1.63T | -84.67B | -4.95% |
| Dec 31, 2022 | 1.71T | 173.49B | 11.28% |
| Dec 31, 2021 | 1.54T | 33.71B | 2.24% |
| Dec 31, 2020 | 1.50T | 147.00B | 10.83% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |
GC Biopharma News
- 22 days ago - MedGenome Makes a Majority Investment in Leading Gujarat-Based Diagnostics Chain Green Cross to Expand Genomics Offerings Across India - Business Upturn